A Phase 1b Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Epacadostat (Primary)
- Indications Solid tumours
- Focus Biomarker; Pharmacodynamics
- 20 Aug 2021 Status changed from recruiting to discontinued.
- 09 Nov 2020 According to an Incyte media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
- 14 Mar 2019 Planned initiation date(estimated date for recruitment of the first subject) changed from 1 February 2019 to 1 April 2019.